Abstract:BACKGROUND & OBJECTIVE:Docetaxel and cisplatin (DDP) are effective drugs for head and neck tumors. Stage II-III clinical trial of TP regimen (docetaxel combined DDP) for head and neck tumors has completed. This study was to compare the efficacy and toxicity of TP regimen and PF regimen [DDP combined 5-fluorouracil (5-FU)] in treating nasopharyngeal carcinoma (NPC), to provide a new chemotherapeutic regimen for NPC. METHODS:Twenty NPC patients treated in Cancer Center of Sun Yat-sen University between Oct. 1, 2005 and Mar. 1, 2006 were subjected to study group (TP group). Twenty patients were chosen randomly from the 45 NPC patients treated with PF regimen between May 1, 2004 and Sep. 30, 2005 as control group (PF group). Both groups received concurrent radiotherapy. The efficacy and adverse events of the 2 groups were compared. RESULTS:The mean number of chemotherapy cycles was significantly higher in TP group than in PF group (3.85 cycles vs. 2.75 cycles, P<0.001). After induction chemotherapy, in TP group, 18 achieved partial remission (PR) and 2 had stable disease (SD) for nasopharyngeal lesions, 7 achieved complete remission (CR), 11 achieved PR and 2 had SD for regional lymph nodes; in PF group, 17 achieved PR and 3 had SD for nasopharyngeal lesions, 2 achieved CR, 15 achieved PR and 1 had SD for regional lymph nodes. After concurrent chemoradiotherapy, all in TP group and 18 in PF group achieved CR for nasopharyngeal lesions, and 19 in TP group and 15 in PF group achieved CR for regional lymph nodes. There was no significant difference in efficacy between the 2 groups (P>0.05). The occurrence rates of grade 3-4 neutropenia were significantly higher in TP group than in PF group (40.5% vs. 0% after induction chemotherapy, 40.5% vs. 10.2% after concurrent radiochemotherapy, P<0.05). The occurrence rates of anemia and thrombocytopenia were significantly lower in TP group than in PF group (P<0.05). The uses of antibiotics and parenteral nutritional support in the 2 groups were similar. CONCLUSION:The efficacy of TP regimen on NPC is similar to that of PF regimen, and the adverse events are tolerable, but the long-term outcomes and toxicities need to be further investigated.

Clinical observation of paclitaxel liposome combined with cisplatin in advanced nasopharyngeal carcinoma

A Clinical Research of Paclitaxel or Docetaxel Combined with Cisplatin in Treating Advanced Nasopharyneal Carcinoma

The efficiency of liposomal paclitaxel versus docetaxel in neoadjuvant chemotherapy with the TPF regimen for locally advanced nasopharyngeal carcinoma: a retrospective study

Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma

Clinical observation of lobaplatin combined with paclitaxel concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma

Paclitaxel + Cisplatin Chemotherapy in Advanced Nasopharynx Carcinoma

The research of clinical effect of paclitaxel liposome plus oxaliplatin combined with radiotherapy for advanced nasopharyngeal carcinoma

Observation on the Clinical Efficacy of Docetaxel Plus Cisplatin and Fluorouracil in Treatment of Patients with Distant Metastatic Nasopharyngeal Carcinoma

Clinical observation of paclitaxel liposome combined with cisplatin in the treatment of patients with advanced esophaeal cancer

[Comparison of Efficacy of Docetaxel Combined Cisplatin (TP Regimen) and Cisplatin Combined 5-Fluorouracil (PF Regimen) on Locally Advanced Nasopharyngeal Carcinoma].

WITHDRAWN: Interim Analysis of a Prospective Randomized Non-Inferiority Trial of Cisplatin and Fluorouracil Induction Chemotherapy with or Without Docetaxel in Nasopharyngeal Carcinoma

Paclitaxel with cisplatin in concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma

Radiation therapy and concomitant weekly paclitaxel for locally advanced nasopharyngeal carcinoma: outcomes of a phase I trial

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma.

Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma

Clinical analysis of paclitaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer

Clinical observation of docetaxel and DF regimen in concurrent chemoradiotherapy for advanced nasopharyngeal carcinoma

Clinical study of inductive chemotherapy with docetaxel plus nedaplatin followed by concurrent nedaplatin with radiotherapy for advanced nasopharyngeal carcinoma

Clinical Study on Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma

Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study

Clinical Study of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Treatment of Patients with Advanced Non-Small-cell Lung Cancer